Abstract Accepted for Prestigious Meeting

Wednesday, July 13, 2005 Abstract Accepted for Prestigious Meeting Results of ongoing research into the efficacy of treating certain prostate cancers with combination therapy consisting of Palladium-103 brachytherapy (seed implant) and supplemental beam radiation, has been accepted for presentation at the annual meeting of the prestigious American Society of Therapeutic Radiation Oncology (ASTRO). The meeting […]

Clinical Outcomes Reported at ASTRO

Sunday, October 17, 2004 Clinical Outcomes Reported at ASTRO Demonstrate Effectiveness of Palladium-103 Brachytherapy in Treatment of Aggressive Prostate Cancer BUFORD, Ga., Oct 17, 2002- Theragenics Corporation(R) (NYSE: TGX) announced today the results of new studies confirming the effectiveness of TheraSeed(R), a Palladium-103 (Pd-103) brachytherapy product, in patients with aggressive cancer who previously were considered […]

Incurable PCa? Consider Brachytherapy

Saturday, May 1, 2004 Incurable PCa? Consider Brachytherapy Over the past decade, prostate brachytherapy has gained increasing popularity for the treatment of prostate cancer, especially in view of the favorable side-effect profile when compared to alternative therapies. The number of patients treated with this modality is now on par with both radical prostatectomy and full-course […]

Radiation First, Then Seed Implant

Thursday, January 1, 2004 Radiation First, Then Seed Implant: More Ammunition to Support this Sequence in the Treatment of Prostate Cancer Perhaps the most contested issue in the combination of external beam radiation with radioactive seed implant treatment for prostate cancer has been the order in which the two therapies are delivered. There have been […]